<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Multimodal Oncology Agent for IDH1 Mutation Prediction in Low-Grade Glioma - Health AI Hub</title>
    <meta name="description" content="This paper introduces a Multimodal Oncology Agent (MOA) designed for accurate IDH1 mutation prediction in low-grade gliomas. The MOA integrates a histology anal">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Multimodal Oncology Agent for IDH1 Mutation Prediction in Low-Grade Glioma</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.05824v1" target="_blank">2512.05824v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-05
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Hafsa Akebli, Adam Shephard, Vincenzo Della Mea, Nasir Rajpoot
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.AI, cs.CV
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.05824v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.05824v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a Multimodal Oncology Agent (MOA) designed for accurate IDH1 mutation prediction in low-grade gliomas. The MOA integrates a histology analysis tool, based on the TITAN foundation model, with a reasoning component that processes structured clinical and genomic data, further enriched by external biomedical sources like PubMed and OncoKB. The agent achieved a superior F1-score of 0.912 when fusing histology features, outperforming clinical, histology, and fused baselines in identifying IDH1 mutations.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Accurate prediction of IDH1 mutations in low-grade gliomas is paramount for precise patient stratification, guiding tailored therapeutic interventions, and providing critical prognostic information. This multimodal agent offers a sophisticated tool to enhance this diagnostic precision, fostering personalized medicine in neuro-oncology.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application is a Multimodal Oncology Agent (MOA) that integrates a histology tool with reasoning over structured clinical and genomic data to accurately predict IDH1 mutations in low-grade glioma patients. This system aims to assist medical professionals in making informed diagnostic, prognostic, and therapeutic decisions by providing crucial mutation status, potentially leading to personalized and more effective cancer treatment strategies.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>IDH1 mutations are critical diagnostic, prognostic, and therapeutic markers in low-grade gliomas (LGGs).</li>
                    
                    <li>The proposed Multimodal Oncology Agent (MOA) combines a histology tool (utilizing the TITAN foundation model) with reasoning capabilities over structured clinical and genomic inputs.</li>
                    
                    <li>MOA enriches its knowledge base by integrating information from external biomedical sources, including PubMed, Google Search, and OncoKB.</li>
                    
                    <li>The agent was quantitatively evaluated on 488 patients from the TCGA-LGG cohort, comparing its performance against clinical and histology baselines.</li>
                    
                    <li>MOA, without the histology tool (relying on clinical/genomic reasoning), achieved an F1-score of 0.826, outperforming the clinical baseline (0.798 F1-score).</li>
                    
                    <li>When histology features were fused, MOA reached its highest performance with an F1-score of 0.912.</li>
                    
                    <li>This peak performance significantly exceeded both the histology baseline (0.894 F1-score) and a fused histology-clinical baseline (0.897 F1-score), demonstrating the capture of complementary mutation-relevant information.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study developed a Multimodal Oncology Agent (MOA) comprising a histology analysis module based on the TITAN foundation model and a reasoning module that processes structured clinical and genomic data. This reasoning module enhances its capabilities by querying external biomedical knowledge bases such as PubMed, Google Search, and OncoKB. The agent's performance was rigorously evaluated using the F1-score on a dataset of 488 low-grade glioma patients from the TCGA-LGG cohort, comparing its predictive accuracy against established clinical, histology, and fused clinical-histology baselines.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The Multimodal Oncology Agent (MOA) significantly improved IDH1 mutation prediction in low-grade gliomas. MOA, utilizing only clinical and genomic reasoning, achieved an F1-score of 0.826, surpassing the clinical baseline's 0.798. Its highest predictive accuracy was observed when fusing histology features with clinical/genomic data, yielding an F1-score of 0.912. This result was superior to both the standalone histology baseline (0.894) and the combined histology-clinical baseline (0.897), indicating effective integration of diverse, complementary information for enhanced prediction.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This MOA has the potential to profoundly impact the clinical management of low-grade gliomas by offering highly accurate and rapid IDH1 mutation predictions. It could serve as a valuable diagnostic aid for pathologists and oncologists, enabling faster and more reliable identification of IDH1-mutant tumors. This precision would facilitate earlier patient stratification, allowing for more targeted and personalized treatment strategies, optimized patient management, and improved prognostic counseling, ultimately advancing precision medicine in neuro-oncology.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any limitations of the proposed agent or the study design.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly mention future research directions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neuro-oncology</span>
                    
                    <span class="tag">Pathology</span>
                    
                    <span class="tag">Cancer Genomics</span>
                    
                    <span class="tag">Computational Pathology</span>
                    
                    <span class="tag">Medical AI</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Glioma</span>
                    
                    <span class="tag tag-keyword">IDH1 mutation</span>
                    
                    <span class="tag tag-keyword">Multimodal AI</span>
                    
                    <span class="tag tag-keyword">Oncology Agent</span>
                    
                    <span class="tag tag-keyword">Histopathology</span>
                    
                    <span class="tag tag-keyword">Prognosis</span>
                    
                    <span class="tag tag-keyword">Personalized Medicine</span>
                    
                    <span class="tag tag-keyword">Machine Learning</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Low-grade gliomas frequently present IDH1 mutations that define clinically distinct subgroups with specific prognostic and therapeutic implications. This work introduces a Multimodal Oncology Agent (MOA) integrating a histology tool based on the TITAN foundation model for IDH1 mutation prediction in low-grade glioma, combined with reasoning over structured clinical and genomic inputs through PubMed, Google Search, and OncoKB. MOA reports were quantitatively evaluated on 488 patients from the TCGA-LGG cohort against clinical and histology baselines. MOA without the histology tool outperformed the clinical baseline, achieving an F1-score of 0.826 compared to 0.798. When fused with histology features, MOA reached the highest performance with an F1-score of 0.912, exceeding both the histology baseline at 0.894 and the fused histology-clinical baseline at 0.897. These results demonstrate that the proposed agent captures complementary mutation-relevant information enriched through external biomedical sources, enabling accurate IDH1 mutation prediction.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>4 pages, 2 figures</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>